<DOC>
	<DOCNO>NCT00477542</DOCNO>
	<brief_summary>This phase trial determine maximum tolerate dose ( MTD ) clofarabine combination myeloablative dose busulfan . This initial step develop novel myeloablative preparative regimen allogeneic hematopoietic stem cell transplantation ( HSCT ) . While phase I trial initially develop regimen patient refractory disease , expect find best application patient less advanced disease</brief_summary>
	<brief_title>A Phase I Trial Myeloablative Conditioning w/ Clofarabine HD Busulfan Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT</brief_title>
	<detailed_description>All patient receive dose busulfan . The dose clofarabine escalate successive cohort patient . Using standard dose escalation design , successive cohort 3 patient treat escalate dos clofarabine . At MTD ( high dose-level MTD reach ) , cohort expand 10 patient well investigate correlative study give preliminary idea efficacy .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Documentation disease . Patients must one follow disease type : Acute myeloid leukemia ( AML ) either : Primary refractory induction chemotherapy Relapsed refractory AML &gt; 5 % blast bone marrow extramedullary disease ( exclude active disease central nervous system ) . Patients second subsequent complete remission ( CR2 , CR3 , etc. ) . Acute lymphoblastic leukemia ( ALL ) one follow criterion : Primary refractory induction chemotherapy . Relapsed refractory ALL &gt; 5 % blast bone marrow extramedullary disease ( exclude active disease central nervous system ) . Patients second subsequent complete remission ( CR2 , CR3 , etc. ) . Myelodysplasia , refractory anemia excess blast 1120 % blast bone marrow ( RAEB II ) . Chronic myelogenous leukemia ( CML ) one follow criterion : Accelerated phase . Patients blast crisis . Patients aggressive nonHodgkin 's lymphoma ( NHL ) , include diffuse large cell lymphoma , mediastinal Bcell lymphoma , transform lymphoma , mantle cell lymphoma , peripheral T cell lymphoma , also one follow criterion : Failure achieve complete remission primary induction therapy Relapsed NHL , refractory least one line salvage systemic therapy Patients relapse &lt; 6 month follow autologous stem cell transplantation eligible . Patient age 1860 year Availability consent HLAmatched donor Performance status ECOG 01 No active infection . Patients active infection require oral intravenous antibiotic eligible enrollment resolution infection . No HIV disease . Patients immune dysfunction significantly high risk infection intensive immunosuppressive therapy . Nonpregnant nonnursing . Treatment protocol would expose fetus significant risk . Women childbearing potential negative pregnancy test prior study entry . Women men reproductive potential agree use appropriate method birth control throughout participation study due teratogenic potential therapy utilized trial . Appropriate method birth control include oral contraceptive , implantable hormonal contraceptive ( Norplant® ) , double barrier method ( diaphragm plus condom ) . Required baseline laboratory value : LVEF &gt; 45 % correct DLCO &gt; 50 % predict value ( correct hemoglobin ) Serum creatinine ≤ 2.0 mg/dl estimate creatinine clearance ≥60 ml/min Bilirubin &lt; 1 x upper limit normal value AST ALT &lt; 1 x upper limit normal value Signed write informed consent . Patient must capable understanding investigational nature investigational nature , potential risk benefit study , able provide valid inform consent . Patients relapse &lt; 6 month follow autologous stem cell transplantation eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Clofarabine</keyword>
	<keyword>allogeneic HSCT</keyword>
	<keyword>refractory malignancy</keyword>
</DOC>